You are here: Home: LCU 3 | 2007: Bruce E Johnson, MD - Select Publications

SELECT PUBLICATIONS

Heymach J et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 7544.

Heymach JV et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc ASCO 2006;Abstract 7016.

Jackman DM et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(13):3908-14. Abstract

Kelly K et al. Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. Proc ASCO 2007;Abstract 7513.

Lynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39. Abstract

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract

Sandler A et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc ASCO 2005;Abstract 4.

Sequist LV et al. iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. Proc ASCO 2007;Abstract 7504.

Shepherd F et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. Abstract

Slotman B et al. A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993). Proc ASCO 2007;Abstract 4.

Socinski MA et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. Proc ASCO 2006;Abstract 7001.

Table of Contents

Top of Page